Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02057692 · ClinicalTrials.gov registry record · Phase 2
Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome
A Phase 2 study, sponsored by Mirum Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT02057692 is a Phase 2 study that has completed, run by Mirum Pharmaceuticals. The registered enrollment target is 37 participants.
The verdict
NCT02057692, a Phase 2 study, has completed, sponsored by Mirum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
The study is a randomized, double-blind, placebo-controlled study in children with Alagille Syndrome (ALGS). The study will investigate the effects of LUM001, compared to placebo, on pruritus, serum bile acids, liver enzymes, and other biochemical markers in patients with ALGS.
Interventions
- DRUG Placebo
- DRUG LUM001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2014-11-24 |
| Est. Completion | 2016-11-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02057692
The ClinicalTrials.gov registry entry for NCT02057692 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirum Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02057692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02057692 about?
NCT02057692 is a clinical study titled "Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome". The study is a randomized, double-blind, placebo-controlled study in children with Alagille Syndrome (ALGS). The study will investigate the effects of LUM001, compared to placebo, on pruritus, serum bile acids, liver enzymes, and other biochemical markers in patients with ALGS.
What is the current status of trial NCT02057692?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2014-11-24. Estimated completion is 2016-11-16.
What interventions are being tested in trial NCT02057692?
The interventions under investigation include: Placebo (DRUG), LUM001 (DRUG).
Who is sponsoring clinical trial NCT02057692?
This trial is sponsored by Mirum Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.